Pfizer gets mixed response on Lyrica NDA

PFE received three approvable letters and one not approvable letter from FDA for Lyrica pregabalin. The approvable letters were for treating diabetic peripheral neuropathy and postherpetic neuralgia and for adjunctive therapy to treat partial seizures in adults. The not approvable letter was for generalized anxiety disorder. ...